All In Biotech

Drug Trial Radar · NCT06308861

Investigate Safety, Tolerability, PK/PK of J2H 1702 in Healthy Males

A Dose Block-randomized, Double-blind, Placebo Controlled, Single and Multiple-dosing, Dose-escalation Phase 1 Clinical Trial to Investigate the Safety, Tolerability, PK/PD of J2H-1702 After Oral Administration in Healthy Male Subjects

Last checked: Nov 20, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Aug 12, 2020

Primary completion

Jun 25, 2021

Study completion Jul 13, 2021

Sponsor

Lead sponsor
J2H BiotechIndustry
Sponsor type
Industry
First posted
Mar 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

1. Research Purpose: To evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic properties of J2H-1702 (a candidate for treatment of non-alcoholic steatohepatitis) in healthy men. 2. Design: A dose block-randomized, double-blind, placebo controlled, single- and multiple dosing, dose-escalation phase 1 clinical trial

Conditions

  • Non-alcoholic Steatohepatitis

Interventions

  • Single administration Amg dose GroupDrug

    Orally, Amg tablet single administration

  • Single administration Bmg dose GroupDrug

    Orally, Bmg tablet single administration

  • Single administration Cmg dose GroupDrug

    Orally, Cmg tablet single administration

  • Single administration Dmg dose GroupDrug

    Orally, Dmg tablet single administration

  • Single administration Emg dose GroupDrug

    Orally, Emg tablet single administration

  • Single administration Amg dose Group-PlaceboDrug

    Orally, Placebo Amg tablet, single administration

  • Single administration Bmg dose Group-PlaceboDrug

    Orally, Placebo Bmg tablet, single administration

  • Single administration Cmg dose Group-PlaceboDrug

    Orally, Placebo Cmg tablet, single administration

  • Single administration Dmg dose Group-PlaceboDrug

    Orally, Placebo Dmg tablet, single administration

  • Single administration Emg dose Group-PlaceboDrug

    Orally, Placebo Emg tablet, single administration

  • Multiple administration Amg dose groupDrug

    Orally, Amg 1 tablet, once a day for 3 days, multiple administration

  • Multiple administration Bmg dose groupDrug

    Orally, Bmg 1 tablet, once a day for 3 days, multiple administration

  • Multiple administration Cmg dose groupDrug

    Orally, Cmg 1 tablet, once a day for 3 days, multiple administration

  • Multiple administration Dmg dose groupDrug

    Orally, Dmg 1 tablet, once a day for 3 days, multiple administration

  • Multiple administration Emg dose groupDrug

    Orally, Emg 1 tablet, once a day for 3 days, multiple administration

  • Multiple administration Amg dose group - PlaceboDrug

    Orally, Placebo Amg 1 tablet, once a day for 3 days, multiple administration

  • Multiple administration Bmg dose group - PlaceboDrug

    Orally, Placebo Bmg 1 tablet, once a day for 3 days, multiple administration

  • Multiple administration Cmg dose group - PlaceboDrug

    Orally, Placebo Cmg 1 tablet, once a day for 3 days, multiple administration

  • Multiple administration Dmg dose group - PlaceboDrug

    Orally, Placebo Dmg 1 tablet, once a day for 3 days, multiple administration

  • Multiple administration Emg dose group - PlaceboDrug

    Orally, Placebo Emg 1 tablet, once a day for 3 days, multiple administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: 1day 0 (Before IP administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours (After IP administration)
  2. EmaxTime frame: -1day 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours, 1day 0 (Before IP administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours (After IP administration)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • J2H Biotech

    Suwon, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.